reason report
basic unchang growth acceler
bottom line deliv solid quarter
basic line compani early-januari commentari
highlight weak cvg cardiac vascular group strength
across part busi help drive solid quarter ep
came us street albeit driven oper incom
notabl manag rais sale guidanc
organ also confid abil
deliv oper growth growth acceler
comp get easier key product launch start contribut
current trade discount broader med-tech
group -- vs group believ
multipl expans hing upon pipelin execut
sale growth trajectori highli lever success
execut current upcom new product launch across
wide rang products/busi manag highlight
deepest promis pipelin ever oper
margin stick point us keep us
get construct share -- start
show good progress improv ytd fx
tailwind continu look clearer sign posit oper
margin expans driver build confid manag
project per year inclin take
conserv stanc need convict behind
pipelin execut consist margin expans believ
valuat increasingli attract rel large-
cap med-tech group investor look rel safe play
volatil market addit stronger gener --
manag guid y/i
midpoint -- balanc sheet believ supplement
growth improv abil activ seek accret
reiter mp pt price target appli
price-to-earnings multipl ep estim assum
share sustain current multipl ep
estim though believ could eventu return
path consist mid-single-digit top-lin growth time less
certain see limit multipl expans
mid-single-digit growth trajectori larg predic new product
launch sustain trend without risk
outlook estim move lower reflect fx headwind
ep unchang estim sale y/
oper report neg fx impact ep
report vs previous mainli
reflect fx headwind oper sale growth
medic suppli devic
ep
net debt total capit
price-to-earnings lt ep growth
year price history/av daili volume mil
compani inform svb leerink llc research
revenu mm ep
pleas refer page import disclosur price chart analyst certif
rate share market perform price target believ
return mid-single-digit top-lin growth trajectori eventu nearli total
sale cardiac rhythm manag spine market estim grow
low-single-digit best mdt sustain growth trajectori larg predic
recent upcom new product launch well success integr covidien
largest acquisit compani histori
ceo omar ishrak helm clearli focus control cost help off-set
on-going price pressur slow market growth broadli med-tech excis tax
name see opportun margin expans combin compani
attempt extract signific cost synergi though compani continu make progress
time extent margin improv still remain challeng increas fx pressur
despit earli sign market stabil market growth recoveri coupl
continu soft spine inclin remain sidelin share
pend clariti execut upcom new product launch help stem
market share loss spine drive market share gain busi
success deliv increment margin expans beyond cov synergi
major med-tech market broadli spine specif experienc real
share trade ep assum stabl multipl
current multipl ep estim moder
area broader large-cap med-tech univers though believ
could eventu return path consist mid-single-digit top-lin growth time less
certain see limit multipl expans mid-single-digit growth
trajectori larg predic recent upcom new product launch sustain
trend without risk price target appli basic stabl
multipl ep estim
risk valuat includ continu signific spine market spine sale declin
market fail regain momentum greater-than-expect drug elut stent de market
share loss greater infus sale declin failur deliv product pipelin failur
success execut cost save initi
dollar million except per share data
good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
consensu detail revenu item includ contributor visibl alpha
consensu estim
compani report factset consensu visibl alpha consensu svb leerink estim
dollar million except per share data
good sold
research develop expens
revenu
consensu incom statement item includ contributor factset
consensu detail revenu item includ contributor visibl alpha
consensu estim
compani report factset consensu visibl alpha consensu svb leerink estim
dollar million except per share data
good sold
research develop expens
pre-tax incom continu oper
net incom continu oper
earn discontinu oper net tax
net incom attribut non-controlling interest
net incom attribut
sg sale
 sale
oper expens sale
revenu report
oper revenu ex fx divestitur
compani report svb leerink estim
medtron plc sale y/i
fx impact neg
impli base
higher end
organ ex fx impact
neg fx impact
higher end
organ ex fx impact
neg fx impact
impact neg
posit fx impact
closer
minu side
full year
impact fx
impact fx
low-double-digit
minu side
full year
low-double-digit
improv
mid high singl
mid high singl
sg
low- mid-teen
similar
low- mid-teen
low- mid-teen
stronger
littl
impli
ep growth
ex fx fx impact
fx impact
impli
ep growth
ex fx fx impact
fx
impli
ep growth
midpoint ex fx
fx
greater
save
ex fx
ex fx
greater
save
ex fx
sg increas
fx posit
greater
save
ex fx
lower half mid-singl
fx
headwind
lower half mid-singl
impact fx
sg increas
flat fx
flat
ex fx
upper end singl digit
rang fx
renal nerv denerv patient hypertens paroxysm
persist atrial fibril purpos clinic studi evalu
feasibl perform renal nerv denerv pulmonari vein isol
patient intent character safeti effect
paroxysm persist atrial fibril popul hypertens assess
safeti studi measur occurr composit safeti endpoint
assess effect studi measur freedom chronic treatment failur
minimum six month follow-up
global clinic studi renal denerv symplic spyral multi-
electrod renal denerv system patient uncontrol hypertens
absenc antihypertens medic
purpos studi obtain assess efficaci safeti
renal denerv absenc antihypertens medic
earli data patient present european societi cardiolog
esc investig found statist signific
clinic import blood pressur reduct patient treat
renal denerv across offic ambulatori systol
earli data first patient enrol prospect
random sham-control spyral htn-on trial present
late-break clinic trial session europcr meet
commenc may pari franc
receiv fda approv begin pivot trial
spyral htn pivot trial random sham-control studi
investig renal denerv procedur patient
site europ australia japan
global clinic studi renal denerv symplic spyral multi-
electrod renal denerv system patient uncontrol hypertens
purpos studi obtain assess efficaci safeti
renal denerv presenc three standard antihypertens medic
spyral htn pivot trial part broader spyral htn global clinic
program multi-phas clinic studi strategi aim establish safeti
efficaci renal denerv lower blood pressur trial investig
blood pressur lower effect safeti renal denerv absenc
medic primari efficaci safeti endpoint trial blood
pressur three month incid major advers event one-month
stand alon cgm system guardian connect launch sugar iq
new cgm system type
